Entering text into the input field will update the search result below

Neurocrine says candidate for childhood epileptic disorder did not meet main goal

Dec. 07, 2022 6:54 AM ETNeurocrine Biosciences, Inc. (NBIX) StockBy: Dulan Lokuwithana, SA News Editor

Arrow missing the target in the darts

leolintang

  • Neurocrine Biosciences (NASDAQ:NBIX) announced that its investigational calcium channel blocker NBI-827104 did not meet the main goal in a Phase 2 trial in patients with the pediatric disorder, epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS).
  • The placebo-controlled

Recommended For You

More Trending News

About NBIX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NBIX--
Neurocrine Biosciences, Inc.